Evidence map›Paper›PMID 39908140›Full record

ArticleCell reports2025

Wnt signaling inhibits casein kinase 1α activity by modulating its interaction with protein phosphatase 2A.

Chen Shen, Wenhui Lu, Siva B Merugu, Aradhana Bharti, Said M Afify, Lauren Schnitkey, Daniel T Wynn, Fan Yang, Thomas M Rohwetter, Anmada Nayak and 11 more

Abstract read
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Chen ShenDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Wenhui LuDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Siva B MeruguDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Aradhana BhartiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Said M AfifyDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Lauren SchnitkeyDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Daniel T WynnDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Fan YangDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Thomas M RohwetterDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Anmada NayakDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Nawat BunnagDepartment of Molecular and Systems Biology and the Dartmouth Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.
Carolina CywiakDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Hsin-Yao TangMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.
Brent T HarrisDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Christopher AlbaneseDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA; Department of Radiology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Chukwuemeka IhemelanduDepartment of Surgical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Melanie H CobbDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Arminja KettenbachDepartment of Molecular and Systems Biology and the Dartmouth Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.
Ethan LeeDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Yashi AhmedDepartment of Molecular and Systems Biology and the Dartmouth Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.
David J RobbinsDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA. Electronic address: dr956@georgetown.edu.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeffrey M Zigman · 2022 to 2026
$7.4M
Mechanism of Wnt signal transductionR35GM122516 · NIGMS · VANDERBILT UNIVERSITY · PI ETHAN LEE · 2017 to 2026
$5.8M
Genetic and Molecular Dissection of Wnt Pathway ActivationSupplementR35GM136233 · NIGMS · DARTMOUTH COLLEGE · PI Yasmath Ahmed · 2020 to 2026
$4.5M
Inhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis ColiR01CA244188 · NCI · DARTMOUTH COLLEGE · PI AHMED, YASMATH, LEE, ETHAN · 2020 to 2024
$3.2M
A Cereblon signaling network in Wnt-driven cancersR01CA281002 · NCI · DARTMOUTH COLLEGE · PI Yasmath Ahmed, ETHAN LEE · 2023 to 2026
$2.6M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Targeting Wnt-dependent colorectal cancerR01CA219189 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ROBBINS, DAVID J · 2018 to 2022
$1.9M
NCI NIH HHS P30 CA023108NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA219189NCI NIH HHS R01 CA244188NCI NIH HHS R01 CA281002NCI NIH HHS R50 CA221838NIDDK NIH HHS P30 DK127984NIGMS NIH HHS R35 GM122516NIGMS NIH HHS R35 GM136233
6 · The paper itself

Abstract

The mechanism by which Wnt signaling, an essential pathway controlling development and disease, stabilizes β-catenin has been a subject of debate over the last four decades. Casein kinase 1α (CK1α) functions as a pivotal negative regulator of this signaling pathway, initiating the events that destabilize β-catenin. However, whether and how CK1α activity is regulated in Wnt-off and Wnt-on states remains poorly understood. We now show that CK1α activity requires its association with the α catalytic subunit of protein phosphatase 2A (PPP2CA) on AXIN, the scaffold protein of the β-catenin destruction complex. Wnt stimulation induces the dissociation of PPP2CA from CK1α, resulting in CK1α autophosphorylation and its consequent inactivation. Moreover, autophosphorylated CK1α is enriched in a subset of colorectal cancers (CRCs) harboring constitutive Wnt activation. Our findings identify a mechanism by which Wnt stimulation inactivates CK1α, filling a critical gap in our understanding of Wnt signaling, with relevance for CRC.

Indexed as

Casein Kinase IalphaProtein Phosphatase 2Wnt Signaling PathwayAxin Proteinbeta CateninCell Line, TumorColorectal NeoplasmsHEK293 CellsHumansPhosphorylationProtein BindingAxin Proteinbeta CateninCasein Kinase IalphaPPP2CA protein, humanProtein Phosphatase 2autophosphorylationCK1αcolorectal cancerCP: CancerCP: Molecular biologyprotein phosphatase 2AWnt signaling

Identifiers

PMID39908140
PMCPMC12829546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.